Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

NCT03575325 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Lymphoid Leukemia
Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia
Relapsed Acute Lymphoblastic Leukemia

Interventions

DRUG: CPX-351

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]